Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4.

Yoo SE, Yi M, Kim WY, Cho SA, Lee SS, Lee SJ, Shin JG.

Drug Metab Pharmacokinet. 2019 Jun;34(3):201-208. doi: 10.1016/j.dmpk.2019.03.001. Epub 2019 Apr 1.

PMID:
30992242
2.

Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.

Lasker JM, Wester MR, Aramsombatdee E, Raucy JL.

Arch Biochem Biophys. 1998 May 1;353(1):16-28.

PMID:
9578596
3.
4.

Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients.

Lanchote VL, Almeida R, Barral A, Barral-Netto M, Marques MP, Moraes NV, da Silva AM, Souza TM, Suarez-Kurtz G.

Br J Clin Pharmacol. 2015 Nov;80(5):1160-8. doi: 10.1111/bcp.12677. Epub 2015 Jul 2.

5.

Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Yousef AM, Bulatova NR, Newman W, Hakooz N, Ismail S, Qusa H, Zahran F, Anwar Ababneh N, Hasan F, Zaloom I, Khayat G, Al-Zmili R, Naffa R, Al-Diab O.

Mol Biol Rep. 2012 Oct;39(10):9423-33. doi: 10.1007/s11033-012-1807-5. Epub 2012 Jun 22.

PMID:
22722998
6.

Genetic contribution to variable human CYP3A-mediated metabolism.

Lamba JK, Lin YS, Schuetz EG, Thummel KE.

Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. Review.

PMID:
12406645
9.

Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.

Störmer E, Brockmöller J, Roots I, Schmider J.

Psychopharmacology (Berl). 2000 Sep;151(4):312-20.

PMID:
11026737
10.
11.

Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.

Wen X, Wang JS, Neuvonen PJ, Backman JT.

Eur J Clin Pharmacol. 2002 Jan;57(11):799-804.

PMID:
11868802
12.

CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.

Wester MR, Lasker JM, Johnson EF, Raucy JL.

Drug Metab Dispos. 2000 Mar;28(3):354-9.

PMID:
10681382
13.

In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.

Zhao K, Ding M, Cao H, Cao ZX.

J Pharm Pharmacol. 2012 Oct;64(10):1445-51. doi: 10.1111/j.2042-7158.2012.01516.x. Epub 2012 May 2.

PMID:
22943175
14.

Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.

Tang SW, Lv XZ, Chen R, Wu SS, Yang ZR, Chen DF, Zhan SY.

Clin Exp Pharmacol Physiol. 2013 May;40(5):326-32. doi: 10.1111/1440-1681.12074.

PMID:
23469989
15.
16.

Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes.

Gao N, Tian X, Fang Y, Zhou J, Zhang H, Wen Q, Jia L, Gao J, Sun B, Wei J, Zhang Y, Cui M, Qiao H.

Eur J Pharm Sci. 2016 Sep 20;92:86-97. doi: 10.1016/j.ejps.2016.06.015. Epub 2016 Jun 23.

PMID:
27339126
17.
18.

Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.

Karam WG, Goldstein JA, Lasker JM, Ghanayem BI.

Drug Metab Dispos. 1996 Oct;24(10):1081-7.

PMID:
8894508
19.

Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.

Nakajima M, Kobayashi K, Oshima K, Shimada N, Tokudome S, Chiba K, Yokoi T.

Xenobiotica. 1999 Sep;29(9):885-98.

PMID:
10548449
20.

Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential.

Furuta S, Akagawa N, Kamada E, Hiyama A, Kawabata Y, Kowata N, Inaba A, Matthews A, Hall M, Kurimoto T.

Br J Clin Pharmacol. 2002 Sep;54(3):295-303.

Supplemental Content

Support Center